Spinefrontier, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.1Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
320clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Inspan $193K associated (2023-2025)
- Sijfuse $186K associated (2023-2025)
- Nanofuse $183K associated (2023-2025)
- Facetfuse $171K associated (2023-2025)
- Sacrix $7,425 associated (2023-2025)
- Vbr $2,000 associated (2023-2025)
- Nanofuse Bioactive Dbm $212 associated (2023-2025)
- Acift $128 associated (2023-2025)
- Pedfuse $110 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Jeffrey Carlson | Newport News, VA | Orthopaedic Surgery of The Spine | $276,743.03 |
| Steven Anagnost | Tulsa, OK | Orthopaedic Surgery of The Spine | $107,519.48 |
| Jeffrey Bash | Middletown, CT | Orthopaedic Surgery of The Spine | $100,451.58 |
| Roger Sung | Colorado Springs, CO | Orthopaedic Surgery of The Spine | $99,327.29 |
| Vivek Kushwaha | Houston, TX | Orthopaedic Surgery of The Spine | $93,015.30 |
| Joseph Aferzon | Portland, CT | Surgery | $51,250.00 |
| Josue Gabriel | Hilliard, OH | Orthopaedic Surgery of The Spine | $42,519.43 |
| Jacob Rosenstein | Arlington, TX | Neurological Surgery | $39,500.00 |
| Ashley Simela | Bronx, NY | Orthopaedic Surgery of The Spine | $30,063.45 |
| Matthew Wasserman | Katy, TX | Orthopaedic Surgery | $28,183.40 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.